Christopher Evans
`
`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Christopher Evans
`Wednesday, December 27, 2017 9:32 AM
`Trials; Michael Shore; Torczon, Richard
`Parmelee, Steve; Rosato, Michael; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com;
`mdzwonczyk@sughrue.com; akokabi@sughrue.com; tribar@sughrue.com; Devine, Wendy; Carsten,
`Douglas; Phillips, Anna; SBloodworth@perkinscoie.com; BMWhite@perkinscoie.com; Mills, Jad;
`IPR13351-0008IP1@fr.com; IPR13351-0008IP2@fr.com; IPR13351-0008IP3@fr.com;
`IPR13351-0008IP4@fr.com; IPR13351-0008IP5@fr.com; IPR13351-0008IP6@fr.com;
`PTABInbound@fr.com; Alfonso G Chan; Joseph DePumpo; marsha@mkschmidtlaw.com;
`whelan@fr.com; coletti@fr.com; oakes@fr.com; singer@fr.com
`RE: IPR2016-01127, -01128, -01129, -01130, -01131, -01132
`
`Your Honors,
`
`The Tribe respectfully renews its request for a telephone conference next week to request permission to
`file a discovery motion. The Tribe will explain why it believes its motion for discovery is
`authorized by 37 C.F.R. § 42.51 under the "interests of justice" category. The Board has previously
`admonished the Tribe's counsel for including legal arguments in its communications with the Board
`so the Tribe has not included any here. Accordingly, the Tribe requests that the Board schedule a call
`to allow the Tribe to fully explain its legal position so that the Board can make an informed ruling.
`
`The Tribe also requests that the Board identify the administrative patent judges currently assigned to
`these proceedings or explain why the current merits panel cannot be publicly disclosed. The Tribe is
`prepared to provide legal arguments concerning this request on the telephone conference.
`
`
`Sincerely,
`
`Chris Evans
`
`From: Trials <Trials@USPTO.GOV> 
`Sent: Wednesday, December 27, 2017 8:55 AM 
`To: Christopher Evans; Michael Shore; Torczon, Richard 
`Cc: Parmelee, Steve; Rosato, Michael; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; 
`mdzwonczyk@sughrue.com; akokabi@sughrue.com; tribar@sughrue.com; Devine, Wendy; Carsten, Douglas; Phillips, 
`Anna; SBloodworth@perkinscoie.com; BMWhite@perkinscoie.com; Mills, Jad; IPR13351‐0008IP1@fr.com; IPR13351‐
`0008IP2@fr.com; IPR13351‐0008IP3@fr.com; IPR13351‐0008IP4@fr.com; IPR13351‐0008IP5@fr.com; IPR13351‐
`0008IP6@fr.com; PTABInbound@fr.com; Alfonso G Chan; Joseph DePumpo; marsha@mkschmidtlaw.com; 
`whelan@fr.com; coletti@fr.com; oakes@fr.com; singer@fr.com 
`Subject: RE: IPR2016‐01127, ‐01128, ‐01129, ‐01130, ‐01131, ‐01132
`
`
`Counsel: 
`
`  
`The Tribe’s request to amend the briefing schedule regarding litigation waiver is granted.  Petitioners’ brief shall 
`be due on January 5, 2018.  The Tribe’s response shall be due on January 12, 2018. 
`
`  
`The Tribe’s request for authorization to file a motion for additional discovery is denied as the information sought 
`is not within the scope of allowable discovery under 37 C.F.R. § 42.51. 
`1
`
`ALL 2116
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`

`

`  
`
`No conference call is necessary at this time. 
`
` 
` 
`Regards, 
`Eric W. Hawthorne 
`Supervisory Paralegal Specialist 
`Patent Trial and Appeal Board 
`  
`  
` 
` 
`From: Christopher Evans [mailto:cevans@ShoreChan.com]  
`Sent: Friday, December 22, 2017 12:28 PM 
`To: Trials <Trials@USPTO.GOV>; Michael Shore <mshore@ShoreChan.com>; Torczon, Richard <rtorczon@wsgr.com> 
`Cc: Parmelee, Steve <sparmelee@wsgr.com>; Rosato, Michael <mrosato@wsgr.com>; gspeier@carlsoncaspers.com; 
`mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; tribar@sughrue.com; Devine, 
`Wendy <wdevine@wsgr.com>; Carsten, Douglas <dcarsten@wsgr.com>; Phillips, Anna <anphillips@wsgr.com>; 
`SBloodworth@perkinscoie.com; BMWhite@perkinscoie.com; Mills, Jad <jmills@wsgr.com>; IPR13351‐0008IP1@fr.com; 
`IPR13351‐0008IP2@fr.com; IPR13351‐0008IP3@fr.com; IPR13351‐0008IP4@fr.com; IPR13351‐0008IP5@fr.com; 
`IPR13351‐0008IP6@fr.com; PTABInbound@fr.com; Alfonso G Chan <achan@ShoreChan.com>; Joseph DePumpo 
`<jdepumpo@ShoreChan.com>; marsha@mkschmidtlaw.com; whelan@fr.com; coletti@fr.com; oakes@fr.com; 
`singer@fr.com 
`Subject: RE: IPR2016‐01127, ‐01128, ‐01129, ‐01130, ‐01131, ‐01132 
`
`  
`Your Honors, 
` 
`
`The Tribe requests a telephone conference to discuss two topics. 
` 
`
`First, the Tribe asks that the briefing deadline be pushed back because of the holidays. The Tribe also
`requests that it be allowed to file its response 7 days after Petitioners file their brief, since the Tribe has
`never seen Petitioners waiver arguments. Thus, the Tribe proposes that Petitioner’s brief to be due on
`January 5, 2018 and the Tribe’s response be due on January 12, 2018.  
` 
`
`Second, the Tribe would like to request permission to file a motion seeking additional discovery on (i) the
`process used by the PTAB to determine the makeup of the panels in the LSI and Ericsson decisions, (ii)
`identification of the judges on the panel who supported the decisions issued in those cases, (iii) how
`different judges filed identical dissents in the two cases, (iv) any policy decisions made by USPTO that
`may have influenced the outcome of those cases, (v) an identification of the Judge’s currently sitting on
`this panel, (vi) the process used to choose those Judges, and (vii) any policy decisions made by USPTO
`that may influence the outcome of this case. The Tribe believes this discovery is authorized by 5 U.S.C.A.
`§ 552(a)(2)(A) and required for the Tribe to be able to adequately address any due process concerns. 
` 
`
`The Petitioners have indicated that they take no position on either of these requests. 
`
`Sincerely, 
`
`Chris Evans 
`  
`  
`  
`
`2
`
`ALL 2116
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`

`

`  
`
` 
`
`Christopher L. Evans 
`Shore Chan DePumpo LLP 
`901 Main Street, Suite 3300 
`Dallas, Texas 75202 
`214-593-9118 (Direct) 
`214-593-9110 (Firm) 
`214-593-9111 (Fax) 
` 
`
`NOTICE OF CONFIDENTIALITY:  
`The information contained in and transmitted with this e-mail may be subject to the Attorney-Client and Attorney Work Product privileges, and is
`Confidential. It is intended only for the individuals or entities designated as recipients above. You are hereby notified that any dissemination, distribution,
`copying, use or reliance upon the information contained in and transmitted with this e-mail by or to anyone other than the addressee designated above by the
`sender is unauthorized and strictly prohibited. If you have received this e-mail in error, please notify the sender by reply immediately. Any e-mail erroneously
`transmitted to you should be immediately destroyed. 
`
`  
`From: Trials [mailto:Trials@USPTO.GOV]  
`Sent: Friday, December 22, 2017 8:04 AM 
`To: Michael Shore <mshore@ShoreChan.com>; Torczon, Richard <rtorczon@wsgr.com> 
`Cc: Parmelee, Steve <sparmelee@wsgr.com>; Christopher Evans <cevans@ShoreChan.com>; Rosato, Michael 
`<mrosato@wsgr.com>; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; 
`akokabi@sughrue.com; tribar@sughrue.com; Devine, Wendy <wdevine@wsgr.com>; Carsten, Douglas 
`<dcarsten@wsgr.com>; Phillips, Anna <anphillips@wsgr.com>; SBloodworth@perkinscoie.com; 
`BMWhite@perkinscoie.com; Mills, Jad <jmills@wsgr.com>; IPR13351‐0008IP1@fr.com; IPR13351‐0008IP2@fr.com; 
`IPR13351‐0008IP3@fr.com; IPR13351‐0008IP4@fr.com; IPR13351‐0008IP5@fr.com; IPR13351‐0008IP6@fr.com; 
`PTABInbound@fr.com; Alfonso G Chan <achan@ShoreChan.com>; Joseph DePumpo <jdepumpo@ShoreChan.com>; 
`marsha@mkschmidtlaw.com; whelan@fr.com; coletti@fr.com; oakes@fr.com; singer@fr.com 
`Subject: RE: IPR2016‐01127, ‐01128, ‐01129, ‐01130, ‐01131, ‐01132 
`
`  
`Counsel: 
`
`  
`Petitioners’ request to file the LSI and Ericsson decisions in these proceedings is denied, as the Board is aware of these 
`decisions. 
`
`  
`Regarding Petitioners’ request for briefing, we authorize both parties to file a 2‐page paper limited to addressing the 
`issue of litigation waiver discussed in the LSI and Ericsson decisions.  To facilitate simultaneous filing, the papers should 
`be filed no later than 5 pm ET on December 29. 
` 
`Regards, 
` 
` 
`Eric W. Hawthorne 
`Supervisory Paralegal Specialist 
`Patent Trial and Appeal Board 
`  
`  
` 
` 
`From: Michael Shore [mailto:mshore@ShoreChan.com]  
`Sent: Thursday, December 21, 2017 10:53 AM 
`To: Torczon, Richard <rtorczon@wsgr.com>; Trials <Trials@USPTO.GOV> 
`Cc: Parmelee, Steve <sparmelee@wsgr.com>; Christopher Evans <cevans@ShoreChan.com>; Rosato, Michael 
`3
`
`ALL 2116
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`

`

`<mrosato@wsgr.com>; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; 
`akokabi@sughrue.com; tribar@sughrue.com; Devine, Wendy <wdevine@wsgr.com>; Carsten, Douglas 
`<dcarsten@wsgr.com>; Phillips, Anna <anphillips@wsgr.com>; SBloodworth@perkinscoie.com; 
`BMWhite@perkinscoie.com; Mills, Jad <jmills@wsgr.com>; IPR13351‐0008IP1@fr.com; IPR13351‐0008IP2@fr.com; 
`IPR13351‐0008IP3@fr.com; IPR13351‐0008IP4@fr.com; IPR13351‐0008IP5@fr.com; IPR13351‐0008IP6@fr.com; 
`PTABInbound@fr.com; Alfonso G Chan <achan@ShoreChan.com>; Joseph DePumpo <jdepumpo@ShoreChan.com>; 
`marsha@mkschmidtlaw.com; whelan@fr.com; coletti@fr.com; oakes@fr.com; singer@fr.com 
`Subject: RE: IPR2016‐01127, ‐01128, ‐01129, ‐01130, ‐01131, ‐01132 
`
`  
`Your Honors, 
`  
`If the Panel is going to consider the issue of litigation waivers, the SRMT thinks a one page brief is enough. In fact, a one 
`sentence brief is enough because litigation waivers do not apply to sovereign tribes, even for compulsory counterclaims 
`related to the same transaction. So unless the board is going to overrule – without the issue even being raised by a party 
`‐‐ multiple federal circuit courts and the United States Supreme Court’s McClendon decision on tribal immunity from 
`counterclaims, the analysis begins and ends with the latest pronouncement on the doctrine in Bodi v Shingle Springs 
`Band of Miwok Indians, 832 F3d 1011, 1018 (9th Cir. 2016).  
`
`  
`To be clear, waiver was never raised by a party, and even if it had been, it does not apply and cannot apply to sovereign 
`tribes as a matter of well‐settled law. The briefing needs to end, a decision needs to be issued and this process needs to 
`conclude. 
`
`  
`Regards, 
`
`  
`Michael W. Shore 
`
`  
`
`  
`From: Torczon, Richard [mailto:rtorczon@wsgr.com]
`Sent: Thursday, December 21, 2017 6:56 AM
`To: Trials
`Cc: Parmelee, Steve; Michael Shore; Christopher Evans; Rosato, Michael; gspeier@carlsoncaspers.com;
`mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; tribar@sughrue.com; Devine,
`Wendy; Carsten, Douglas; Phillips, Anna; SBloodworth@perkinscoie.com; BMWhite@perkinscoie.com; Mills, Jad;
`IPR13351-0008IP1@fr.com; IPR13351-0008IP2@fr.com; IPR13351-0008IP3@fr.com; IPR13351-0008IP4@fr.com;
`IPR13351-0008IP5@fr.com; IPR13351-0008IP6@fr.com; PTABInbound@fr.com; Alfonso G Chan; Joseph DePumpo;
`marsha@mkschmidtlaw.com; whelan@fr.com; coletti@fr.com; oakes@fr.com; singer@fr.com
`Subject: RE: IPR2016-01127, -01128, -01129, -01130, -01131, -01132 
`
`  
`Your Honors: 
`
` 
`Contrary to the Tribe’s assertion below, Petitioner Mylan, as well as the BSA amicus, argued
`that the Tribe’s willing participation in the parallel district court proceedings was a waiver of its
`immunity. See Paper 121 at 7 (Mylan) and Paper 117 at 14-15 (BSA), respectively, both citing
`Vas-Cath 473 F.3d at 1383. In light of the Tribe’s waiver assertion below, Mylan requests leave
`to submit a two-page brief to address the intervening decisions noted below. 
`
` 
`The Tribe opposes this request. Allergan did not respond. 
`
` 
`Respectfully, 
`Richard Torczon 
`
`  
`
`4
`
`ALL 2116
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`

`

`Reg. No. 34,448 
`For Petitioner Mylan 
`
` 
`From: Michael Shore [mailto:mshore@ShoreChan.com]
`Sent: Wednesday, 20 December, 2017 14.14
`To: Torczon, Richard; Trials
`Cc: Parmelee, Steve; Christopher Evans; Rosato, Michael; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com;
`mdzwonczyk@sughrue.com; akokabi@sughrue.com; tribar@sughrue.com; Devine, Wendy; Carsten, Douglas; Phillips,
`Anna; SBloodworth@perkinscoie.com; BMWhite@perkinscoie.com; Mills, Jad; IPR13351-0008IP1@fr.com; IPR13351-
`0008IP2@fr.com; IPR13351-0008IP3@fr.com; IPR13351-0008IP4@fr.com; IPR13351-0008IP5@fr.com; IPR13351-
`0008IP6@fr.com; PTABInbound@fr.com; Alfonso G Chan; Joseph DePumpo; marsha@mkschmidtlaw.com;
`whelan@fr.com; coletti@fr.com; oakes@fr.com; singer@fr.com
`Subject: RE: IPR2016-01127, -01128, -01129, -01130, -01131, -01132 
`
`  
`Your Honors, 
`
`  
`To respond to the inappropriate “Mylan notes” argument in Mr. Torczon’s email, the SRMT “notes” that the opinions 
`found a “litigation waiver” that has not been alleged or argued by Requesters, and was therefore waived as a ground for 
`maintaining the action and cannot be considered or relied upon by this panel to sustain jurisdiction. 
`
`  
`Michael W. Shore 
`
`  
`From: Torczon, Richard [mailto:rtorczon@wsgr.com]
`Sent: Wednesday, December 20, 2017 1:09 PM
`To: Trials
`Cc: Parmelee, Steve; Christopher Evans; Rosato, Michael; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com;
`mdzwonczyk@sughrue.com; akokabi@sughrue.com; tribar@sughrue.com; Devine, Wendy; Carsten, Douglas; Phillips,
`Anna; SBloodworth@perkinscoie.com; BMWhite@perkinscoie.com; Mills, Jad; IPR13351-0008IP1@fr.com; IPR13351-
`0008IP2@fr.com; IPR13351-0008IP3@fr.com; IPR13351-0008IP4@fr.com; IPR13351-0008IP5@fr.com; IPR13351-
`0008IP6@fr.com; PTABInbound@fr.com; Alfonso G Chan; Joseph DePumpo; Michael Shore; marsha@mkschmidtlaw.com;
`whelan@fr.com; coletti@fr.com; oakes@fr.com; singer@fr.com
`Subject: RE: IPR2016-01127, -01128, -01129, -01130, -01131, -01132 
`
`  
`Your Honors, 
`
` 
`Petitioner Mylan Pharmaceuticals Inc. requests authorization to submit to the panel copies of yesterday’s
`expanded-panel decisions on State sovereign immunity. LSI Corp. v. Regents of the University of Minnesota,
`IPR2017-01068, Paper 19; and Ericsson Inc. v. Regents of the University of Minnesota, IPR2017-01186, Paper
`16. Mylan notes these opinions, including the concurrences, as well as the arguments put forth by Mylan and
`the amicus briefs, provide many alternative and non-exclusive bases for maintaining jurisdiction. Mylan does
`not believe additional briefing is needed. 
`
`  
`The Tribe has indicated that it does not oppose filing these opinions. 
`
` 
`Respectfully submitted, 
`Richard Torczon 
`Reg. No. 34,448 
`For Petitioner Mylan 
`  
`
`Richard Torczon | Wilson Sonsini Goodrich & Rosati | 1700 K Street NW, Fifth Floor | Washington, D.C. 20006 
`Main: 202.973.8800 | Direct: 202.973.8811 | Facsimile: 202.973.8899 | www.wsgr.com 
`
`
`This email and any attachments thereto may contain private, confidential, and privileged material for
`5
`
`ALL 2116
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`

`

`the sole use of the intended recipient. Any review, copying, or distribution of this email (or any
`attachments thereto) by others is strictly prohibited. If you are not the intended recipient, please
`contact the sender immediately and permanently delete the original and any copies of this email and
`any attachments thereto.
`
`6
`
`ALL 2116
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`